Bristol-Myers Squibb Company v. Sigmapharm Laboratories, No. 20-2229 (Fed. Cir. Sept. 3, 2021)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Having reviewed the district court’s thorough and thoughtful opinion, we affirm. We specifically adopt its construction of the following terms from U.S. Patent No. 6,967,208 (“the ’208 patent”): (1) “substituted with [N] R,” see Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., 477 F. Supp. 3d 306, 340 (D. Del. 2020), and (2) “phar- maceutically acceptable salts,” see id. at 312 ¶ 13. And, we adopt its construction of the following terms from U.S. Pa- tent No.